Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences
Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.
Transcript (slightly modified) What would you like to see included in the next generation of value assessment frameworks to better identify value?
In the next generation of value assessment frameworks, we need to make sure that they are able to account for patient preference in a way that the patient and the physician can understand what is the value of a therapy given a patient’s specific set of preferences. To do this, we need to do a few things. First, we need to think about preferences much earlier in the development process. This way we can make sure that therapies are developed with patient preferences in mind, and then the clinical outcomes that are designed to measure the efficacy of those therapies are the outcomes that matter to patients.
Once we have those outcomes, patient preferences need to be incorporated into the actual value assessment and then, finally, the value assessment must offer a range of values to represent the spectrum of patient preferences.